ClinicalTrials.gg
RecruitingNCT05824871WISHUpdated Jun 29, 2025

A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients

A Phase 3 interventional study of Sudapyridine and Bedaquiline in Rifampin-Resistant Pulmonary Tuberculosis and Tuberculosis, Multidrug-Resistant (MDR-TB), sponsored by Shanghai Jiatan Pharmatech Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Shanghai Jiatan Pharmatech Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Sep 2022, registered Apr 2023).
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Tuberculosis with a site in China — 22 open to participants now, 25 under way, 5 of them phase 3. Tuberculosis · China.

Planned enrollment
16th of 47
450 · median 241
Started
2022
with 4 others
Phase 3
10 of 62
4 open now
Primary completion
2025-12
later than 4 of 24 live
Registered
36th of 62
by date
Lead sponsor
2 of 62
Shanghai Jiatan Pharmatech Co., Ltd

Among the 62 studies in Tuberculosis with a site in China, this one is the 16th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2022, is one of 10 in phase 3, reaches primary completion later than 4 of the 24 other live ones, and was the 36th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

22 of the 62 studies in Tuberculosis with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Tuberculosis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, active-controlled Phase III study to evaluate the efficacy and safety of Sudapyridine (WX-081) combined with a background regimen (BR) in patients with rifampicin-resistant pulmonary tuberculosis.

Approximately 450 participants will be screened over a period of up to 2 weeks and randomized in a 2:1 ratio to receive either Sudapyridine or bedaquiline, in combination with placebo tablets and BR, for 24 weeks. After the treatment period, participants will enter a background regimen period up to Week 72, during which they will continue to receive BR.

A subset of participants will be included in the C-QT sub-study to assess intensive PK sampling and 12-lead ECG evaluations on Day 1 pre-dose, Day 14, and Week 24.

The study aims to provide robust data to support the use of Sudapyridine as a treatment option for rifampicin-resistant pulmonary tuberculosis.

Read the detailed description

This Phase III clinical study is designed to evaluate the efficacy and safety of Sudapyridine (WX-081) in combination with a background regimen (BR) for the treatment of rifampicin-resistant pulmonary tuberculosis. The study will be conducted at multiple centers, employing a randomized, double-blind, active-controlled design.

The study will consist of three phases:

Screening Phase:

Duration: Up to 2 weeks. Approximately 450 participants with rifampicin-resistant pulmonary tuberculosis will be screened for eligibility.

Treatment Phase:

Participants will be randomized in a 2:1 ratio into two groups:

  1. Sudapyridine Group: Sudapyridine (WX-081) with placebo and BR.
  2. Bedaquiline Group: Bedaquiline with placebo and BR. Treatment duration: 24 weeks.

Background Regimen Phase:

After completing the treatment phase, participants in both groups will continue to receive the background regimen (BR) until Week 72.

The study aims to test the hypothesis that Sudapyridine (WX-081), when combined with a background regimen, is effective and safe for treating rifampicin-resistant pulmonary tuberculosis. The data collected from this study will include primary and secondary endpoints related to efficacy and safety, PK/PD data, and cardiac safety evaluations.

The sample size of approximately 450 participants is designed to provide adequate power to detect a statistically significant difference in outcomes between treatment groups. Comprehensive data validation procedures and a robust statistical analysis plan will ensure the reliability and accuracy of the results.

03

Conditions studied

  • Rifampin-Resistant Pulmonary Tuberculosis
  • Tuberculosis, Multidrug-Resistant (MDR-TB)

Keywords

  • Rifampin-Resistant Tuberculosis
  • Multidrug-Resistant Tuberculosis (MDR-TB)
  • Pulmonary Tuberculosis
  • Sudapyridine (WX-081)
  • Bedaquiline
  • Antitubercular Agents
  • Randomized Controlled Trial
  • Background Regimen Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • (BMI) and body weight of subjects: 15.0≤BMI≤28.0 kg/m2, and 40kg≤ body weight ≤90kg;

      • For clinically diagnosed patients with tuberculosis whose drug sensitivity test has proved to be at least resistant to rifampicin, phenotypic or molecular drug sensitivity test results within 3 months before the subject signs can be accepted;
      • Direct sputum smear positive for acid-fast bacilli (AFB at least 1+);
      • Willing to discontinue all previous anti-tuberculosis drugs and accept a 7-day ;
      • Non-lactating and pregnant women who agree to use throughout the treatment; Or the male patient's spouse agrees to use contraception throughout the treatment.

Exclusion criteria

Exclusion Criteria:

    • Allergic to any study drug or its ingredients;

      • A history of alcohol dependence or drug abuse;
      • With hematogenous disseminated pulmonary tuberculosis or extrapulmonary tuberculosis;
      • Drug susceptibility test before screening showed resistance to more than 4 of the 8 antituberculosis drugs in this study;
      • Have taken Bedaquiline before;
      • -positive patients;
      • Laboratory obvious abnormalities;
      • A history of pointy torsion ventricular tachycardia or cardiac risk factors for pointy torsion ventricular tachycardia;
      • Repeated intervals > 450ms; ventricular arrhythmias that may require medical or surgical treatment;
      • Documented cardiovascular diseases;
      • Peripheral neuropathy grade 3 or grade 4; Grade 1 or grade 2 neuropathy that the investigator believes is likely to progress/worsen over the course of the study; optic neuritis;
      • Any serious cardiovascular, kidney, liver, blood, tumor, endocrine and metabolic, or rheumatic diseases.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Sudapyridine (WX-081) Group

    Participants in this group will receive Sudapyridine (WX-081) combined with background regimen (BR). Treatment starts with a loading dose of Sudapyridine for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days). This is followed by a maintenance dose of 150 mg once daily from Week 3 to Week 24. During the 24-week treatment period, participants will also receive a placebo for bedaquiline and continue their background regimen (BR). After the 24-week treatment period, participants will enter the background regimen phase and continue BR until Week 72.

    Drug: Sudapyridine

  • Active comparator
    Bedaquiline Group

    Participants in this group will receive Bedaquiline combined with background regimen (BR). Treatment starts with a loading dose of Bedaquiline for 2 weeks (400 mg once daily), followed by a maintenance dose of 200 mg three times per week (with at least 48 hours between doses) from Week 3 to Week 24. During the 24-week treatment period, participants will also receive a placebo for Sudapyridine and continue their background regimen (BR). After the 24-week treatment period, participants will enter the background regimen phase and continue BR until Week 72.

    Drug: Bedaquiline

Interventions

  • Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.

    Also known as: WX-081

  • Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.

06

What researchers measure

Primary outcomes

  1. Sputum Culture Conversion Rate at Week 24

    Proportion of participants achieving sputum culture conversion (SCC) at Week 24 of treatment, measured as a percentage.

    Time frame: Week 24

Secondary outcomes

  1. Time to Sputum Culture Conversion

    Time required for participants to achieve sputum culture conversion (SCC) during the study period.

    Time frame: Up to Week 72

  2. Treatment Success Rate at Week 72

    Proportion of participants achieving treatment success at Week 72, based on predefined criteria.

    Time frame: Week 72

  3. Sputum Culture Conversion Rates at Multiple Time Points

    Proportion of participants achieving sputum culture conversion at Weeks 8, 12, 16, 20, 36, 48, 60, and 72.

    Time frame: Up to Week 72

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2025, 39 months after the start.

Of 40 phase 3 interventional studies under Tuberculosis, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 76. This study's planned 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
Apr 24, 2023
StartActual
Sep 2, 2022
Primary completionEst.
Dec 22, 2025
CompletionEst.
Oct 22, 2026
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05824871
Lead sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Sep 2, 2022
Primary completion
Dec 22, 2025 (estimated)
Completion
Oct 22, 2026 (estimated)
Last update
Jun 29, 2025

Study contacts

Naihui Chu, MD
Contact
dongchu1994@sina.com
010-89509312
Zhao Jie, Ph.D
Contact
jiaojie_zhao@126.com
86010-89509157
Naihui Chu, Ph.D
principal investigator · Beijing Chest Hospital affiliated to Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sudapyridine

Start the discussion